Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes

This article covers the reabsorption of glucose mechanism in the kidneys, the functional mechanism of various Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, their structure and driving profile, and a few SGLT2 inhibitors now accessible in the market as well as those in different periods of advancement. The advantages of SGLT2 inhibitors are dose-dependent glycemic regulation changes with a significant reduction both in the concentration of HbA1c and body weight clinically and statistically. A considerable number of SGLT2 inhibitors have been approved by the FDA, while a few others, still in preliminaries, have shown interesting effects.PMID:34538233 | DOI:10.2174/1573399817666210917122745

Source: Current Diabetes Reviews - September 20, 2021 Category: Endocrinology Authors: Shivani Sharma Amit Mittal Shubham Kumar Anu Mittal Source Type: research